Evidence map›Paper›PMID 28197653›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2017

Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.

A Botticella, G Defraene, K Nackaerts, C Deroose, J Coolen, P Nafteux, B Vanstraelen, S Joosten, L A W Michiels, S Peeters and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Safety and efficacy of helical tomotherapy following lung-sparing surgery in locally advanced malignant pleural mesothelioma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A BotticellaDepartment of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium. angela.botticella@kuleuven.be.
G DefraeneDepartment of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
K NackaertsDepartment of Respiratory Medicine, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium.
C DerooseNuclear Medicine, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium.
J CoolenRadiology Department, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium.
P NafteuxDepartment of Thoracic Surgery, University Hospitals Leuven, 3000, Leuven, Belgium.
B VanstraelenDepartment of Radiation Oncology, University Hospitals Leuven, 3000, Leuven, Belgium.
S JoostenInstitute Paramedical Studies, Medical Imaging and Radiotherapeutic Techniques, Fontys University of Applied Science, Eindhoven, The Netherlands.
L A W MichielsInstitute Paramedical Studies, Medical Imaging and Radiotherapeutic Techniques, Fontys University of Applied Science, Eindhoven, The Netherlands.
S PeetersDepartment of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
D De RuysscherDepartment of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation. MATERIALS AND

methodsIn all, 12 consecutive stage I-IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured. Two sets of planning target volumes (PTV) were generated for each patient: (1) a "selective" PTV (S-PTV), originating from a 5-mm isotropic expansion from the GTV and (2) an "elective" PTV (E-PTV), originating from a 5-mm isotropic expansion from the whole ipsilateral pleural space. Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a "selective" pleural irradiation plan (SPI plan) and an "elective" pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]).

resultsIn the SPI plans, the average median dose to the S‑PTV was 53.6 Gy (range 41-63.6 Gy). In 4 of 12 patients, it was possible to escalate the dose to the S‑PTV to >58 Gy. In the EPI plans, the average median doses to the E‑PTV and to the S‑PTV were 48.6 Gy (range 38.5-58.7) and 49 Gy (range 38.6-59.5 Gy), respectively. No significant dose escalation was achievable.

conclusionThe omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.

Indexed as

Dose Fractionation, RadiationDose-Response Relationship, RadiationFemaleHumansMaleMesotheliomaMiddle AgedPleuraPleural NeoplasmsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedElective pleural irradiationLung-sparing VMATMalignant pleural mesotheliomaNonsurgical treatmentsSelective pleural irradiation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.